HC Wainwright Weighs in on Shattuck Labs, Inc.’s FY2025 Earnings (NASDAQ:STTK)

Shattuck Labs, Inc. (NASDAQ:STTK) – Research analysts at HC Wainwright lowered their FY2025 earnings per share (EPS) estimates for Shattuck Labs in a research note issued to investors on Wednesday, April 10th. HC Wainwright analyst J. Pantginis now expects that the company will earn ($2.00) per share for the year, down from their prior forecast of ($1.95). HC Wainwright currently has a “Buy” rating and a $28.00 target price on the stock. The consensus estimate for Shattuck Labs’ current full-year earnings is ($1.85) per share.

Separately, Needham & Company LLC reiterated a “buy” rating and issued a $12.00 price target on shares of Shattuck Labs in a research note on Tuesday, April 9th.

Shattuck Labs Stock Performance

STTK stock opened at $9.09 on Monday. The company has a market capitalization of $431.50 million, a PE ratio of -4.43 and a beta of 2.11. The company’s fifty day moving average price is $9.14 and its 200-day moving average price is $6.17. Shattuck Labs has a one year low of $1.33 and a one year high of $11.11.

Shattuck Labs (NASDAQ:STTK) last posted its quarterly earnings results on Thursday, February 29th. The company reported ($0.41) earnings per share for the quarter, topping the consensus estimate of ($0.51) by $0.10. The business had revenue of $0.71 million during the quarter, compared to the consensus estimate of $0.50 million. Shattuck Labs had a negative return on equity of 63.08% and a negative net margin of 5,268.44%.

Hedge Funds Weigh In On Shattuck Labs

Several institutional investors have recently bought and sold shares of STTK. Acadian Asset Management LLC bought a new position in shares of Shattuck Labs in the 1st quarter valued at about $37,000. Squarepoint Ops LLC purchased a new stake in Shattuck Labs during the first quarter valued at approximately $30,000. UBS Group AG lifted its stake in shares of Shattuck Labs by 62.3% in the 1st quarter. UBS Group AG now owns 10,978 shares of the company’s stock valued at $32,000 after purchasing an additional 4,214 shares during the last quarter. Balyasny Asset Management LLC purchased a new position in shares of Shattuck Labs in the 3rd quarter worth approximately $35,000. Finally, Tower Research Capital LLC TRC boosted its holdings in shares of Shattuck Labs by 79.2% in the 4th quarter. Tower Research Capital LLC TRC now owns 13,553 shares of the company’s stock worth $97,000 after purchasing an additional 5,989 shares during the period. Institutional investors own 58.74% of the company’s stock.

Insider Buying and Selling at Shattuck Labs

In other Shattuck Labs news, insider Stephen Stout sold 16,004 shares of Shattuck Labs stock in a transaction that occurred on Wednesday, March 6th. The stock was sold at an average price of $10.53, for a total value of $168,522.12. Following the sale, the insider now owns 74,437 shares of the company’s stock, valued at approximately $783,821.61. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 9.46% of the stock is currently owned by company insiders.

About Shattuck Labs

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.